Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Brief summary

The goal of this Phase I/II observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors. The study utilizes multi-dimensional precision screening (including WES, RNAseq, mIHC, and quantitative proteomics) to match patients with specific sub-protocols. Key questions it aims to answer: Assess the safety of innovative therapies in rare tumor populations. Evaluate the objective response rate (ORR) and other efficacy metrics. Explore biomarkers related to therapeutic efficacy. Participants: Patients with metastatic or advanced rare solid tumors who have failed standard therapy or have no standard treatment options.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

NOT_YET_RECRUITING

phase

PHASE1, PHASE2

study type

INTERVENTIONAL

enrollment

600

sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

conditions

Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors

interventions

DRUG: BL-B01D1; DRUG: VSV injection; DRUG: CVL006; BIOLOGICAL: IDOV-SAFE; BIOLOGICAL: KXV01 TCR Lentinvivo Injection; BIOLOGICAL: MT027; BIOLOGICAL: QH101; BIOLOGICAL: Meta10-TIL; BIOLOGICAL: TAEST1901; BIOLOGICAL: TC-N201

start date

2026-01-01

start date type

ESTIMATED

primary completion date

2029-01-31

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters